Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsIn 2022, SOLASIA PHARMA K.K. O.N. has already paid €0.27 in dividends. The last payout was in March 2022.
Financials
In the last quarter, SOLASIA PHARMA K.K. O.N. had revenue of €1.89m and net profit of -€565.93k
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 1.89m | 683.19% |
| Gross profit | 958.16k | 436.83% |
| Net profit | -565.93k | 42.52% |
| EBITDA | -543.52k | 42.79% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €40.8m |
Number of shares | 273.01m |
52-week high/low | €0.24 - €0.12 |
| Dividends | No |
Beta | 1.18 |
P/E ratio | -8.55 |
PEG ratio | -0.10 |
P/B ratio | 5.28 |
P/S ratio | 10.38 |
Company profile
Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.
| Name | SOLASIA PHARMA K.K. O.N. |
| CEO | Yoshihiro Arai |
| Headquarters | Tokyo,
ty Japan |
| Website | |
| IPO | 27/03/2017 |
| Employees | 22 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Japan Exchange Group | 4597.T |
Frankfurt | 9SO.F |